Business Wire

MERCY-SHIPS

31.5.2022 07:32:04 CEST | Business Wire | Press release

Share
H.E. President Macky Sall Leads Inauguration of the World’s Largest Purpose-built Hospital Ship, the Global Mercy™

H.E. President of Senegal Macky Sall has inaugurated the world’s largest purpose-built hospital ship and committed to accelerate access to surgical, obstetric and anesthetic care for the nations of Africa. Ceremonies commemorated more than 30 years of service in Africa. International humanitarian organization Mercy Ships and its partners in Africa used the opportunity to come together in an unprecedented and strategic effort to improve access to safer surgery across the continent through a series of milestone events.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220530005472/en/

Representatives from Cameroon, the Union of Comoros, Congo Brazzaville, The Gambia, Guinea-Bissau, and Senegal, gathered on board the Global Mercy to approve a strategic road map to improve surgical care for African nations by 2030, where an estimated 93% of sub-Saharan Africa still lack access to safe surgery.

H.E. President Macky Sall greeted the Heads of State, saying, “We, heads of states present this day, have adopted the Dakar Declaration, which is the result of the meticulous work of our ministers and experts on access to surgical, obstetric and aesthetic care. As President in Office for the African Union, I commit to bring the Dakar Declaration to the summit of heads of state and African governments.”

Gert van de Weerdhof, Mercy Ships Chief Executive Officer said, “At the end of a difficult week for Senegal and for all of us after the tragic events that happened; today, I want to greet you all on this special day here in Dakar, Senegal. The inauguration of the Global Mercy is only one part of the reason we celebrate today. Big decisions have been made here in Dakar.”

President of the Union of the Comoros, Azali Assoumani said, “I pay tribute to Senegal as well as the personnel of Mercy Ships for their commitment to this mission. I applaud this model cooperation contributing to the strengthening of our surgical, obstetric, and anesthetic systems in Africa.”

The Dakar Declaration is an historic agreement following foundational discussions from an International Symposium in Senegal held May 4 – 6, 2022 where experts and ministers of health from 29 African nations met to put forward their commitment to advancing access to surgical, obstetric, and anesthetic care. The result of the Symposium brought a fresh initiative to draft a clear path toward safer and wider access to surgical care in Africa by 2030. Symposium members shared knowledge of their countries’ surgical care situations, addressed gaps and challenges in their national surgical, obstetric and anesthetic plans, and developed new strategies for implementation and capacity building. Prior to the International Symposium, a baseline assessment was carried out with each country and evaluated by a scientific committee.

A first of its kind in Africa, this study has so far collected data about the availability, access, and operation of surgical, obstetric, and anesthetic healthcare systems in 29 of the 47 nations of WHO’s sub-Saharan African region. The survey provides critical insights into Africa’s healthcare systems from the perspective of district hospitals, particularly in the area of surgery. The World Health Organization will leverage the results of the study to complete the ongoing situational analysis of clinical and hospital services, as well as develop and finalize the regional strategy for strengthening clinical and hospital services in Africa.

The comprehensive preliminary report developed by members of the scientific committee led to the drafting of a roadmap to scale up investment in the strengthening of surgical, obstetric, anesthetic, and nursing care in Africa, in line with the Sustainable Development Goals (SDG). A draft Dakar Declaration was prepared and endorsed by the Ministers of Health and approved by visiting African Heads of State.

The new hospital ship, Global Mercy ™ is 174 meters long, 28.6 meters wide and has space for 200 patients, six operating rooms, one laboratory, general outpatient clinics, a dental clinic, and an eye clinic. The hospital decks cover a total area of 7,000 square meters and contain the latest training facilities. When in full service, the ship will be able to accommodate up to 950 people when docked, including crew members and volunteers from all over the world.

A recording of the inauguration ceremony can be found here: https://www.youtube.com/watch?v=HylOGBYaX-0 .

ABOUT MERCY SHIPS:

Global health for the last two decades has focused on individual diseases, while surgical care in low-resource countries has not received the attention it needs. Lack of surgical care resulted in almost 17 million deaths annually.

Mercy Ships is an international faith-based organization that operates hospital ships to deliver free, world-class healthcare services, medical capacity building, and health system strengthening to those with little access to safe surgical care. Since 1978, Mercy Ships has worked in more than 55 countries, with the last three decades focused entirely on partnering with African nations. Each year, volunteer professionals from over 60 countries serve on board the world’s two largest non-governmental hospital ships, the Africa Mercy® and the Global Mercy™. Professionals such as surgeons, dentists, nurses, health trainers, cooks, and engineers dedicate their time and skills to the cause. Mercy Ships has offices in 16 countries and an Africa Bureau. For more information, visit mercyships.org and follow us @MercyShips on social media.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye